Santen Pharmaceutical Co., Ltd.
Santen Pharmaceutical Co., Ltd.
Your view on SNPHF
Overview
What the company does, where it operates, and who runs it.
About Santen Pharmaceutical Co., Ltd.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Takeshi Ito
- Headquarters
- Grand Front Osaka Tower A, Osaka, JP
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Takeshi Ito
- Headquarters
- Grand Front Osaka Tower A, Osaka, JP
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally.
It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial.
In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis.
Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia.
Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Santen Pharmaceutical Co., Ltd., and the rating behind it. SNPHF last traded at $9.51, 14.5× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Santen Pharmaceutical Co., Ltd.. Starting points for Santen Pharmaceutical Co., Ltd.: P/E 14.5, EPS $120.36, beta 0.34 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Santen Pharmaceutical Co., Ltd.. Santen Pharmaceutical Co., Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Santen Pharmaceutical Co., Ltd.. Trailing twelve-month EPS for Santen Pharmaceutical Co., Ltd. stands at $120.36. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Santen Pharmaceutical Co., Ltd.. Santen Pharmaceutical Co., Ltd. has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Santen Pharmaceutical Co., Ltd. valued side by side against its closest peers. Santen Pharmaceutical Co., Ltd. is measured against Drug Manufacturers - General peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Santen Pharmaceutical Co., Ltd., and how their positions are changing. At a $3.06B market value, institutional positions materially move Santen Pharmaceutical Co., Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Santen Pharmaceutical Co., Ltd. executives and directors. Shares of Santen Pharmaceutical Co., Ltd. have traded between $8.88 and $12.64 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Santen Pharmaceutical Co., Ltd.. Santen Pharmaceutical Co., Ltd. is a $3.06B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Santen Pharmaceutical Co., Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Santen Pharmaceutical Co., Ltd.. Coverage tracks Santen Pharmaceutical Co., Ltd. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.